LLY vs PG: Which Is the Better Buy?
Side-by-side comparison of Eli Lilly and Company and The Procter & Gamble Company — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-04.
Eli Lilly and Company · Healthcare
$934.34
+98.6% upside to fair value
Grade B
High Quality
VS
The Procter & Gamble Company · Consumer Defensive
$143.45
+13.8% upside to fair value
Grade B
High Quality
QuantHub Verdict
LLY has more upside to fair value
(+98.6%).
PG trades at a lower forward P/E
(20.8x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
LLY |
PG |
| Current Price |
$934.34 |
$143.45 |
| Fair Value Estimate |
$1,855.91 |
$163.27 |
| Upside to Fair Value |
+98.6%
|
+13.8%
|
| Market Cap |
$882.8B |
$334.0B |
| Forward P/E |
33.1x
|
20.8x
|
| EV / EBITDA |
27.9x
|
15.4x
|
| Price / Sales |
12.2x
|
3.9x
|
| Price / FCF |
65.0x
|
22.2x
|
| Revenue Growth YoY |
+55.5%
|
+7.4%
|
| Gross Margin |
82.7%
|
50.3%
|
| Operating Margin |
46.3%
|
23.2%
|
| Return on Equity |
101.3%
|
31.3%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
1.54%
|
4.5%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
Eli Lilly and Company is a leading global pharmaceutical firm with a dominant position in the diabetes and obesity markets, driven by its blockbuster GLP-1 drugs Mounjaro and Zepbound which generated $36.5 billion in FY2025. The company reported $65.2 billion in total revenue for 2025, making it the top pharma by revenue globally. It exhibits high business quality with a durable competitive moat …
The Procter & Gamble Company is a leading consumer defensive firm specializing in household and personal products with a diversified portfolio across fabric and home care, baby and family care, beauty, health care, and grooming segments. The business quality is high, supported by durable brands, strong margins with a 50.3% gross margin and 19.2% net margin, and consistent earnings growth evidence…
Accumulation Zones
| Metric |
LLY |
PG |
| Zone Low |
$1,391.93 |
$122.45 |
| Zone High |
$1,577.52 |
$138.78 |
| In Buy Zone? |
Yes
|
No
|